Call Us @ 0172 - 4680800 | info@indswift.com | NETWORKS | NSE - BSE
Biocon introduces oncologic biosimilar KRABEVA in India.
 
Biotechnology major Biocon today said it has launched its cancer biosimilar drug KRABEVA in India.

The biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India, Biocon said in a filing to the BSE. Biocon CEO and Joint MD Arun Chandavarkar said: "With KRABEVA, we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer."

The company believes that the product will be an important addition to its oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India, he added.

KRABEVA is the second key oncologic biosimilar product from Biocon's global biosimilar portfolio to be launched in India to address the unmet patient need for affordable, biological therapies, the company said.

"It is being offered to patients at an MRP of Rs 24,000 for 100 mg/4 ml vials and Rs 39,990 for 400 mg/16 ml vials...," it added.

Stock of Biocon was today trading at Rs 412.80 on the BSE, up 1.03 per cent from its previous close.

(TIMES OF INDIA)
(www.timesofindia.in)
 
Other Related News:
2019 FDA Approved Drugs
FDA announces another carcinogenic impurity in ARB blood pressure drugs
Researchers identify common genetic signature among three rare skin diseases
Health ministry to amend Section 71 of D&C Rules to make Pharm D professionals eligible to supervise drug manufacturing
3rd International Diabetes Summit to be held in Pune from March 8-10, 2019
Health ministry to roll out common IT platform for management of sales and manufacturing licenses of drugs
Cosmetics licences may come with product composition details to enhance safety; new clause proposed in Cosmetics Rules 2018
T-cell specificity found to play a role in attacks on myelin versus β-synuclein in MS
Plazomicin noninferior to meropenem for complicated UTI
New molecules reverse memory loss linked to depression, aging